ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ObsEva SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.
South Korea
092040
AMICUS THERAPEUTICS, INC. Logo
Develops advanced therapies for rare lysosomal storage disorders.
United States of America
FOLD
AMINOLOGICS CO.,LTD. Logo
Manufactures high-purity chiral amino acids & APIs for pharma, chemical, and food industries.
South Korea
074430
Amneal Pharmaceuticals, Inc. Logo
Develops & commercializes essential medicines: generics, injectables & specialty drugs.
United States of America
AMRX
Amphastar Pharmaceuticals, Inc. Logo
Develops and manufactures complex injectable, intranasal, and inhalation pharmaceutical products.
United States of America
AMPH
Amylyx Pharmaceuticals, Inc. Logo
Developing novel therapies for neurodegenerative diseases like ALS and Wolfram syndrome.
United States of America
AMLX
AN2 Therapeutics, Inc. Logo
Developing novel small molecule drugs for infectious diseases and oncology using boron chemistry.
United States of America
ANTX
Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.
United Kingdom
ANAN
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.
United States of America
ANAB
Develops qPCR diagnostic kits and robotic automation systems for clinical and research laboratories.
Türkiye
ANGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.